Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients

AIDS Research and Human Retroviruses
Pedro CastroFelipe García

Abstract

Vaccination is recommended for HIV-infected patients. Transient increases of viral load (VL) and risk of developing resistance to HAART have been described. In addition, VL rebounds could increase HIV-specific immune responses. Twenty-six successfully treated HIV-infected adults were randomized to receive a vaccination schedule or placebo during 12 months. Afterward, HAART was discontinued. Influences of vaccination over VL, genotypic mutations, different T cell subsets, and HIV-1-specific immune responses were evaluated. Patients did not present any secondary effect. No differences in incidence of detectable VL determinations were detected between groups [relative risk 0.54 (95% CI 0.23-1.26)]. No relevant resistance mutations were detected. The vaccinated group showed a significant drop in CD4(+) T cells (p = 0.046) associated with increases in activated T cells. HIV-1-specific lymphoproliferative responses increased more in the vaccinated group during the vaccination period. Viral rebound dynamics after interrupting HAART were similar in both groups. A vaccination schedule in successfully treated HIV patients was safe, was not associated with an increase in detectable VL, and did not increase the risk of developing resistanc...Continue Reading

References

Feb 1, 1992·AIDS Research and Human Retroviruses·G Poli, A S Fauci
Feb 1, 1989·Current Opinion in Immunology·J L Virelizier
Dec 1, 1995·The Journal of Experimental Medicine·S I StapransM B Feinberg
Sep 2, 1997·Proceedings of the National Academy of Sciences of the United States of America·G PantaleoA S Fauci
Apr 8, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R B Couch
Jul 6, 2000·The Journal of Experimental Medicine·V AppayS L Rowland-Jones
Mar 23, 2001·Nature Immunology·M D HazenbergF Miedema
Jul 13, 2001·JAMA : the Journal of the American Medical Association·D V HavlirJ K Wong
Apr 3, 2002·Nature Medicine·Zvi GrossmanWilliam E Paul
May 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Livio AzzoniLuis J Montaner
Sep 28, 2002·AIDS·Gilbert GreubUNKNOWN Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study
Apr 16, 2003·The Journal of Infectious Diseases·Carol A KemperUNKNOWN California Collaborative Treatment Group
Sep 17, 2003·The Journal of Clinical Investigation·Guido Silvestri, Mark B Feinberg
Jun 24, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Montserrat PlanaJose M Gatell
Sep 10, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eric FlorenceJosé M Gatell
Oct 16, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark R WallaceSybil A Tasker
Oct 21, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephen C De RosaMario Roederer
Apr 12, 2005·AIDS·Rodolphe ThiébautUNKNOWN Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA)
Jul 12, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Manuel L Fernández GuerreroMiguel De Górgolas
Feb 7, 2006·Trends in Immunology·Christine A JansenFrank Miedema
Dec 1, 2006·The New England Journal of Medicine·UNKNOWN Strategies for Management of Antiretroviral Therapy (SMART) Study GroupC Rappoport

❮ Previous
Next ❯

Citations

Jun 2, 2011·The Journal of Infectious Diseases·Odile LaunayUNKNOWN ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vacci
Apr 20, 2011·Immunology·Montserrat PlanaUNKNOWN Red de Investigación en Sida (RIS)
May 29, 2012·Human Vaccines & Immunotherapeutics·Bao-Chau Phung, Odile Launay
Oct 11, 2014·The Cochrane Database of Systematic Reviews·Mbah P OkwenLawrence Mbuagbaw
Dec 6, 2012·Clinical Pharmacology and Therapeutics·K M BartonD M Margolis
May 14, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Pedro CastroFelipe García
Aug 18, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Chloé Wyndham-ThomasViolette Dirix
Jan 7, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Csaba FehérPatrick Aloy

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
flow cytometry
genotyping

Clinical Trials Mentioned

NCT00329251

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.